Immunomodulatory Effects Mediated by Dopamine

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Arreola, Rodrigo ^a   Alvarez Herrera, Samantha ^a   Pérez Sánchez, Gilberto ^a   Becerril Villanueva, Enrique ^a   Cruz Fuentes, Carlos ^a   Flores Gutierrez, Enrique Octavio ^a   Garcés Alvarez, María Eugenia ^a   De La Cruz Aguilera, Dora Luz ^b   Medina Rivero, Emilio ^c   Hurtado Alvarado, Gabriela ^d   Quintero Fabián, Saray ^e   Pavón, Lenin ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c Unidad de Investigación y Desarrollo Cruce de Carreteras Acatzingo Zumpahuacán   (Mexico)

^d DEPARTAMENTO DE QUÍMICA   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2; DOPAMINE RECEPTOR;

ADIPOSE TISSUE; ALCOHOL WITHDRAWAL SYNDROME; ALCOHOLISM; ANGIOGENESIS; ARTHRITIS; B LYMPHOCYTE; CARDIOVASCULAR SYSTEM; CATABOLISM; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GAME ADDICTION; GLOMERULONEPHRITIS; GRANULOCYTE; HEMATOPOIESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LESCH NYHAN SYNDROME; LIVER MICROSOME; MACROPHAGE; MESENTERIC ARTERY; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; CYTOLOGY; DEGENERATIVE DISEASE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKOCYTE; MENTAL DISEASE; METABOLISM; PERIPHERAL NERVOUS SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; LEUKOCYTES; MENTAL DISORDERS; METABOLIC NETWORKS AND PATHWAYS; NEURODEGENERATIVE DISEASES; ORGAN SPECIFICITY; PERIPHERAL NERVOUS SYSTEM; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION;

EID: 84992436563     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/3160486     Document Type: Review

References (282)

1. R. Franco, R. Pacheco, C. Lluis, G. P. Ahern, and P. J. O'Connell, "The emergence of neurotransmitters as immune modulators, " Trends in Immunology, vol. 28, no. 9, pp. 400-407, 2007.
2. S. Basu and P. S. Dasgupta, "Dopamine, a neurotransmitter, influences the immune system, " Journal of Neuroimmunology, vol. 102, no. 2, pp. 113-124, 2000.
3. M. Cosentino and F. Marino, "Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: Teaching old drugs new tricks" Journal of Neuroimmune Pharmacology, vol. 8, no. 1, pp. 163-179, 2013.
4. G. E. Torres, "The dopamine transporter proteome, " Journal of Neurochemistry, vol. 97, supplement 1, pp. 3-10, 2006.
5. R. Pacheco, T. Gallart, C. Lluis, and R. Franco, "Role of glutamate on T-cell mediated immunity, " Journal of Neuroimmunology, vol. 185, no. 1-2, pp. 9-19, 2007.
6. K. F. Atkinson, S. H. Kathem, X. Jin et al., "Dopaminergic signaling within the primary cilia in the renovascular system, " Frontiers in Physiology, vol. 6, article 103, 2015.
7. R. Arreola, E. Becerril-Villanueva, C. Cruz-Fuentes et al., "Immunomodulatory effects mediated by serotonin, " Journal of Immunology Research, vol. 2015, Article ID 354957, 21 pages, 2015.
8. Y. Zhang, S. Cuevas, L. D. Asico et al., "Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure, " PLoS ONE, vol. 7, no. 6, Article IDe38745, 2012.
9. D. C. Borcherding, E. R. Hugo, G. Idelman et al., "Dopamine receptors in human adipocytes: expression and functions, " PLoS ONE, vol. 6, no. 9, Article ID e25537, 2011.
10. S. Cuevas, V. A. Villar, P. A. Jose, and I. Armando, "Renal dopamine receptors, oxidative stress, and hypertension, " International Journal of Molecular Sciences, vol. 14, no. 9, pp. 17553-17572, 2013.
11. B. Rub and P. Maechler, "Minireview: new roles for peripheral dopamine onmetabolic control and tumor growth: let's seek the balance, " Endocrinology, vol. 151, no. 12, pp. 5570-5581, 2010.
12. J.-H. Baik, "Dopamine signaling in reward-related behaviors, " Frontiers in Neural Circuits, vol. 7, article 152, 2013.
13. N. Ben-Jonathan and R. Hnasko, "Dopamine as a prolactin (PRL) inhibitor, " Endocrine Reviews, vol. 22, no. 6, pp. 724-763, 2001.
14. J. D. Salamone, M. Pardo, S. E. Yohn, L. Lopez-Cruz, N. San-Miguel, and M. Correa, "Mesolimbic dopamine and the regulation of motivated behavior, " Current Topics in Behavioral Neurosciences, vol. 27, pp. 231-257, 2016.
15. J.-M. Beaulieu and R. R. Gainetdinov, "The physiology, signaling, and pharmacology of dopamine receptors, " Pharmacological Reviews, vol. 63, no. 1, pp. 182-217, 2011.
16. J.-M. Beaulieu, S. Espinoza, and R. R. Gainetdinov, "Dopamine receptors-IUPHAR review 13, " British Journal of Pharmacology, vol. 172, no. 1, pp. 1-23, 2015.
17. G. C. Beck, P. Brinkkoetter, C. Hanusch et al., "Clinical review: immunomodulatory effects of dopamine in general inflammation, " Critical Care, vol. 8, no. 6, pp. 485-491, 2004.
18. N. Ayala-Lopez, M. Martini, W. F. Jackson et al., "Perivascular adipose tissue contains functional catecholamines, " Pharmacology Research&Perspectives, vol. 2, no. 3, Article IDe00041, 2014.
19. E. Nagy, I. Berczi, G. E. Wren, S. L. Asa, andK. Kovacs, "Immunomodulation by bromocriptine, " Immunopharmacology, vol. 6, no. 3, pp. 231-243, 1983.
20. J. Bergquist, A. Tarkowski, R. Ekman, and A. Ewing, "Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop, " Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 12912-12916, 1994.
21. M. Levite, "Nerve-driven immunity. The direct effects of neurotransmitters on T-cell function, " Annals of the New York Academy of Sciences, vol. 917, pp. 307-321, 2000.
22. I. Berczi, A. Quintanar-Stephano, and K. Kovacs, "Neuroimmune regulation in immunocompetence, acute illness, and healing, " Annals of the New York Academy of Sciences, vol. 1153, pp. 220-239, 2009.
23. I. J. Elenkov, R. L. Wilder, G. P. Chrousos, and E. S. Vizi, "The sympathetic nerve-an integrative interface between two supersystems: The brain and the immune system, " Pharmacological Reviews, vol. 52, no. 4, pp. 595-638, 2000.
24. M. Cosentino, E. Rasini, C. Colombo et al., "Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptordependent protective effect, " Free Radical Biology andMedicine, vol. 36, no. 10, pp. 1233-1240, 2004.
25. G. Barger and H. H. Dale, "Chemical structure and sympathomimetic action of amines, " The Journal of Physiology, vol. 41, no. 1-2, pp. 19-59, 1910.
26. H. Blaschko, "The activity of l(-)-dopa decarboxylase, " The Journal of Physiology, vol. 101, no. 3, pp. 337-349, 1942.
27. C. Mannich, W. Jacobsohn, and Hr. C. Mannich, " Über oxyphenyl-alkylamine und dioxyphenyl-alkylamine, " Berichte der Deutschen Chemischen Gesellschaft, vol. 43, no. 1, pp. 189-197, 1910.
28. G. Barger and P. G. Ewins, "Some phenolic derivatives of beta phenylethyl-amine, " Journal of the Chemical Society, vol. 97, p. 8, 1910.
29. O. Hornykiewicz, "Dopamine miracle: from brain homogenate to dopamine replacement, " Movement Disorders, vol. 17, no. 3, pp. 501-508, 2002.
30. D. L. Roe, "The discovery of dopamine's physiological importance, " Brain Research Bulletin, vol. 50, no. 5-6, pp. 375-376, 1999.
31. C. A. Marsden, "Dopamine: The rewarding years, " British Journal of Pharmacology, vol. 147, supplement 1, pp. S136-S144, 2006.
32. A. Bertler and E. Rosengren, "Occurrence and distribution of dopamine in brain and other tissues, " Experientia, vol. 15, no. 1, pp. 10-11, 1959.
33. K. M. Ashe, W.-L. Chiu, A. M. Khalifa et al., "Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain, " Neuroendocrinology Letters, vol. 32, no. 3, pp. 253-258, 2011.
34. M. K. Sievert, A. R. Hajipour, and A. E. Ruoho, "Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels, " Analytical Biochemistry, vol. 367, no. 1, pp. 68-78, 2007.
35. A. Carlsson, M. Lindqvist, and T. Magnusson, "3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists, " Nature, vol. 180, no. 4596, p. 1200, 1957.
36. A. Carlsson, M. Lindqvist, T. Magnusson, and B. Waldeck, "On the presence of 3-hydroxytyramine in brain, " Science, vol. 127, no. 3296, p. 471, 1958.
37. H. Sano, "Biochemistry of the extrapyramidal system Shinkei Kennkyu No Shinpo, Advances in Neurological Sciences. (ISSN 0001-8724) Tokyo, October 1960;5:42-48, " Parkinsonism & Related Disorders, vol. 6, no. 1, pp. 3-6, 1960.
38. H. Ehringer and O. Hornykiewicz, "Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system, " Parkinsonism and Related Disorders, vol. 4, no. 2, pp. 53-57, 1998.
39. W. Birkmayer and O. Hornykiewicz, "The effect of l-3, 4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism, " Parkinsonism and Related Disorders, vol. 4, no. 2, pp. 59-60, 1998.
40. C. Leiva, "Madopar: more than 20 years, " Revue Neurologique, vol. 25, no. 148, pp. 1957-1963, 1997.
41. P. J. Garca Ruiz and E. Meseguer, "Short history of L-Dopa, " Neurologia, vol. 17, no. 4, pp. 214-217, 2002.
42. E. Tolosa, M. J. Marti, and F. Valldeoriola, "History of levodopa and dopamine agonists in Parkinson's disease treatment, " Neurology, vol. 50, no. 6, supplement 6, pp. S2-S10, 1998.
43. R. A. Hauser, "Levodopa: past, present, and future, " European Neurology, vol. 62, no. 1, pp. 1-8, 2009.
44. P. Teismann, K. Tieu, D.-K. Choi et al., "Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5473-5478, 2003.
45. U. Ungerstedt, L. L. Butcher, S. G. Butcher, N.-E. Andén, and K. Fuxe, "Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat, " Brain Research, vol. 14, no. 2, pp. 461-471, 1969.
46. J. W. Kebabian and P. Greengard, "Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission, " Science, vol. 174, no. 4016, pp. 1346-1349, 1971.
47. J. W. Kebabian, G. L. Petzold, and P. Greengard, "Dopaminesensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the 'dopamine receptor', " Proceedings of the National Academy of Sciences of the United States of America, vol. 69, no. 8, pp. 2145-2149, 1972.
48. J. W. Kebabian, "Multiple classes of dopamine receptors in mammalian central nervous system: The involvement of dopamine-sensitive adenylyl cyclase, " Life Sciences, vol. 23, no. 5, pp. 479-483, 1978.
49. P. F. Spano, S. Govoni, and M. Trabucchi, "Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system, " Advances in Biochemical Psychopharmacology, vol. 19, pp. 155-165, 1978.
50. S. Shimada, S. Kitayama, C.-L. Lin et al., "Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA, " Science, vol. 254, no. 5031, pp. 576-578, 1991.
51. J. E. Kilty, D. Lorang, and S. G. Amara, "Cloning and expression of a cocaine-sensitive rat dopamine transporter, " Science, vol. 254, no. 5031, pp. 578-579, 1991.
52. B. Giros, S. El Mestikawy, L. Bertrand, and M. G. Caron, "Cloning and functional characterization of a cocaine-sensitive dopamine transporter, " FEBS Letters, vol. 295, no. 1-3, pp. 149-154, 1991.
53. T. B. Usdin, E. Mezey, C. Chen, M. J. Brownstein, and B. J. Hoffman, "Cloning of the cocaine-sensitive bovine dopamine transporter, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11168-11171, 1991.
54. B. Giros, S. el Mestikawy, N. Godinot et al., "Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter, " Molecular Pharmacology, vol. 42, no. 3, pp. 383-390, 1992.
55. Physiology or Medicine for 2000-Press Release.
56. A. Baudry, A. Alleaume-Butaux, S. Dimitrova-Nakov et al., "Essential roles of dopamine and serotonin in tooth repair: functional interplay between odontogenic stem cells and platelets, " Stem Cells, vol. 33, no. 8, pp. 2586-2595, 2015.
57. I. Armando, P. Konkalmatt, R. A. Felder, and P. A. Jose, "The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease, " Translational Research, vol. 165, no. 4, pp. 505-511, 2015.
58. D. S. Goldstein and C. Holmes, "Neuronal source of plasma dopamine, " Clinical Chemistry, vol. 54, no. 11, pp. 1864-1871, 2008.
59. G. Eisenhofer, A. Aneman, P. Friberg et al., "Substantial production of dopamine in the human gastrointestinal tract, " Journal of Clinical Endocrinology andMetabolism, vol. 82, no. 11, pp. 3864-3871, 1997.
60. J. L. Willems, W. A. Buylaert, R. A. Lefebvre, and M. G. Bogaert, "Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system, " Pharmacological Reviews, vol. 37, no. 2, pp. 165-216, 1985.
61. J. Meiser, D. Weindl, and K. Hiller, "Complexity of dopamine metabolism, " Cell Communication and Signaling, vol. 11, article 34, 2013.
62. F. Amenta, A. Ricci, I. Rossodivita, R. Avola, and S. K. Tayebati, "The dopaminergic systemin hypertension, " Clinical and Experimental Hypertension, vol. 23, no. 1-2, pp. 15-24, 2001.
63. P. A. Jose, G. M. Eisner, and R. A. Felder, "Regulation of blood pressure by dopamine receptors, " Nephron, vol. 95, no. 2, pp. p19-p27, 2003.
64. C. R. Jackson, G.-X. Ruan, F. Aseem et al., "Retinal dopamine mediates multiple dimensions of light-adapted vision, " The Journal of Neuroscience, vol. 32, no. 27, pp. 9359-9368, 2012.
65. D. E. Hernandez, G. A. Mason, C. H. Walker, and J. E. Valenzuela, "Dopamine receptors in human gastrointestinal mucosa, " Life Sciences, vol. 41, no. 25, pp. 2717-2723, 1987.
66. A. Maffei, A. M. Segal, J. C. Alvarez-Perez, A. Garcia-Ocaña, and P. E. Harris, "Anti-incretin, anti-proliferative action of dopamine on-cells, " Molecular Endocrinology, vol. 29, no. 4, pp. 542-557, 2015.
67. N. Simpson, A. Maffei, M. Freeby et al., "Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro, "Molecular Endocrinology, vol. 26, no. 10, pp. 1757-1772, 2012.
68. R. Bhattacharya, S. Sinha, S.-P. Yang et al., "The neurotransmitter dopamine modulates vascular permeability in the endothelium, " Journal of Molecular Signaling, vol. 3, article 14, 2008.
69. B. A. Faraj, Z. L. Olkowski, and R. T. Jackson, "Binding of3H-dopamine to human lymphocytes: possible relationship to neurotransmitter uptake sites, " Pharmacology, vol. 42, no. 3, pp. 135-141, 1991.
70. B. Bondy, M. Ackenheil, R. Elbers, and M. Fröhler, "Binding of 3H-spiperone to human lymphocytes: A biological marker inschizophrenia" Psychiatry Research, vol. 15, no. 1, pp. 41-48, 1985.
71. B. Bondy, M. Ackenheil, and T. Ruppert, "Spiperone binding in lymphocytes: part of a dopamine uptake system" Annals of the New York Academy of Sciences, vol. 650, pp. 221-225, 1992.
72. S. Basu, P. Sarathi Dasgupta, T. Lahiri, and J. Roy Chowdhury, "Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice, " Life Sciences, vol. 53, no. 5, pp. 415-424, 1993.
73. A. Ricci and F. Amenta, "Dopamine D5 receptors in human peripheral blood lymphocytes: A radioligand binding study, " Journal of Neuroimmunology, vol. 53, no. 1, pp. 1-7, 1994.
74. B. Dean, A. J. McAdam, S. Sundram, G. Pavey, L. C. Harrison, and D. L. Copolov, "Identification of a dopamine-binding protein on the membrane of the human platelet, " Biochemical Journal, vol. 287, no. 1, pp. 45-50, 1992.
75. C. Prado, F. Contreras, H. González et al., "Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity, " The Journal of Immunology, vol. 188, no. 7, pp. 3062-3070, 2012.
76. B. Basu, C. Sarkar, D. Chakroborty et al., "D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in Jurkat T leukemic cells, " The Journal of Biological Chemistry, vol. 285, no. 35, pp. 27026-27032, 2010.
77. M. Ferrari, M. Cosentino, F. Marino et al., "Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes, " Biochemical Pharmacology, vol. 67, no. 5, pp. 865-873, 2004.
78. E. J. Meredith, M. J. Holder, A. Rosén et al., "Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: implications for non-Hodgkin's lymphoma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 36, pp. 13485-13490, 2006.
79. P. J. Gaskill, L. Carvallo, E. A. Eugenin, and J. W. Berman, "Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse, " Journal of Neuroinflammation, vol. 9, article 203, 2012.
80. P. J. Gaskill, T. M. Calderon, A. J. Luers, E. A. Eugenin, J. A. Javitch, and J. W. Berman, "Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: A bridge between HIV-associated neurologic disorders and drug abuse, " The American Journal of Pathology, vol. 175, no. 3, pp. 1148-1159, 2009.
81. H. Liang, X. Wang, H. Chen et al., "Methamphetamine enhances HIV infection of macrophages, " American Journal of Pathology, vol. 172, no. 6, pp. 1617-1624, 2008.
82. W. Zhao, Y. Huang, Z. Liu, B.-B. Cao, Y.-P. Peng, and Y.-H. Qiu, "Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway, " PLoS ONE, vol. 8, no. 6, Article IDe65860, 2013.
83. M. Cosentino, A. M. Fietta, M. Ferrari et al., "Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop, " Blood, vol. 109, no. 2, pp. 632-642, 2007.
84. J. Kipnis, M. Cardon, H. Avidan et al., "Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration, " The Journal of Neuroscience, vol. 24, no. 27, pp. 6133-6143, 2004.
85. N. Kustrimovic, E. Rasini, M. Legnaro, F. Marino, and M. Cosentino, "Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease, " Journal of Neuroimmune Pharmacology, vol. 9, no. 3, pp. 302-312, 2014.
86. Y. Watanabe, T. Nakayama, D. Nagakubo et al., "Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3, " Journal of Immunology, vol. 176, no. 2, pp. 848-856, 2006.
87. Y. Huang, A.-W. Qiu, Y.-P. Peng, Y. Liu, H.-W. Huang, and Y.-H. Qiu, "Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function, " Neuroendocrinology Letters, vol. 31, no. 6, pp. 782-791, 2010.
88. F. McKenna, P. J. McLaughlin, B. J. Lewis et al., "Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: A flow cytometric study, " Journal of Neuroimmunology, vol. 132, no. 1-2, pp. 34-40, 2002.
89. M. C. Ghosh, A. C. Mondal, S. Basu et al., "Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells, " International Immunopharmacology, vol. 3, no. 7, pp. 1019-1026, 2003.
90. M. J. Besser, Y. Ganor, and M. Levite, "Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNF or both, " Journal of Neuroimmunology, vol. 169, no. 1-2, pp. 161-171, 2005.
91. L. Liu, G. Yuan, Z. Cheng, G. Zhang, X. Liu, and H. Zhang, "Identification of the mRNA expression status of the dopamine D2 receptor and dopamine transporter in peripheral blood lymphocytes of schizophrenia patients, " PLoS ONE, vol. 8, no. 9, Article ID e75259, 2013.
92. J. Mikulak, L. Bozzo, A. Roberto et al., "Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor, " The Journal of Immunology, vol. 193, no. 6, pp. 2792-2800, 2014.
93. G. P. Kirillova, R. J. Hrutkay, M. R. Shurin, G. V. Shurin, I. L. Tourkova, and M. M. Vanyukov, "Dopamine receptors in human lymphocytes: radioligand binding and quantitative RTPCR assays, " Journal of NeuroscienceMethods, vol. 174, no. 2, pp. 272-280, 2008.
94. F. Amenta, E. Bronzetti, L. Felici, A. Ricci, and S. K. Tayebati, "Dopamine D2-like receptors on human peripheral blood lymphocytes: A radioligand binding assay and immunocytochemical study, " Journal of Autonomic Pharmacology, vol. 19, no. 3, pp. 151-159, 1999.
95. Y. Nagai, S. Ueno, Y. Saeki, F. Soga, and T. Yanagihara, "Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes, " Biochemical and Biophysical Research Communications, vol. 194, no. 1, pp. 368-374, 1993.
96. A. Ricci, E. Bronzetti, L. Felici, S. Greco, and F. Amenta, "Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: A combined radioligand binding assay and immunochemical study, " Journal of Neuroimmunology, vol. 92, no. 1-2, pp. 191-195, 1998.
97. T. Ilani, R. D. Strous, and S. Fuchs, "Dopaminergic regulation of immune cells viaD3 dopamine receptor: A pathway mediated by activated T cells, " The FASEB Journal, vol. 18, no. 13, pp. 1600-1602, 2004.
98. C. Strell, A. Sievers, P. Bastian et al., "Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes, " BMC Immunology, vol. 10, article 62, 2009.
99. B. Bondy, S. de Jonge, S. Pander, J. Primbs, and M. Ackenheil, "Identification of dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction, " Journal of Neuroimmunology, vol. 71, no. 1-2, pp. 139-144, 1996.
100. C. Sarkar, S. Das, D. Chakroborty et al., "Cutting edge: stimulation of dopamine D4 receptors induce T cell quiescence by upregulating Krüppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation, " The Journal of Immunology, vol. 177, no. 11, pp. 7525-7529, 2006.
101. N. Takahashi, Y. Nagai, S. Ueno, Y. Saeki, and T. Yanagihara, "Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes, " FEBS Letters, vol. 314, no. 1, pp. 23-25, 1992.
102. A. Ricci, E. Bronzetti, F. Mignini, S. K. Tayebati, D. Zaccheo, and F. Amenta, "Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes, " Journal of Neuroimmunology, vol. 96, no. 2, pp. 234-240, 1999.
103. F. Amenta, E. Bronzetti, F. Cantalamessa et al., "Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes, " Journal of Neuroimmunology, vol. 117, no. 1-2, pp. 133-142, 2001.
104. F. R. Buttarelli, A. Circella, C. Pellicano et al., "Dopamine transporter immunoreactivity in peripheral blood lymphocytes inmultiple system atrophy, " Journal of Neural Transmission, vol. 116, no. 2, pp. 161-165, 2009.
105. D. Marazziti, M. Catena Dell'Osso, S. Baroni et al., "Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders, " Psychiatry Research, vol. 175, no. 1-2, pp. 54-57, 2010.
106. B. Caronti, G. Tanda, C. Colosimo et al., "Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease, " NeuroReport, vol. 10, no. 14, pp. 2907-2910, 1999.
107. X.-Y. Zhao, S.-W. Cui, X.-Q. Wang, Y.-P. Peng, and Y.-H. Qiu, "Tyrosine hydroxylase expression in CD4+ T cells is associated with joint inflammatory alleviation in collagen type II-induced arthritis, " Rheumatology International, vol. 33, no. 10, pp. 2597-2605, 2013.
108. Y.-H. Qiu, C. Cheng, L. Dai, and Y.-P. Peng, "Effect of endogenous catecholamines in lymphocytes on lymphocyte function, " Journal of Neuroimmunology, vol. 167, no. 1-2, pp. 45-52, 2005.
109. I. Kokkinou, E. Nikolouzou, A. Hatzimanolis, E. G. Fragoulis, and D. Vassilacopoulou, "Expression of enzymatically active LDOPA decarboxylase in human peripheral leukocytes, " Blood Cells, Molecules, and Diseases, vol. 42, no. 1, pp. 92-98, 2009.
110. I. Kokkinou, E. G. Fragoulis, and D. Vassilacopoulou, "The U937 macrophage cell line expresses enzymatically active l-Dopa decarboxylase, " Journal of Neuroimmunology, vol. 216, no. 1-2, pp. 51-58, 2009.
111. R. C. Alaniz, S. A. Thomas, M. Perez-Melgosa et al., "Dopamine-hydroxylase deficiency impairs cellular immunity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 2274-2278, 1999.
112. U. Grimm, A. Knapp, A. Weber, G. Seidlitz, and M. Wehnert, "Detection of phenylalanine hydroxylase activity in leukocytes and fibroblasts, " Biomedica Biochimica Acta, vol. 42, no. 9, pp. 1135-1141, 1983.
113. G. A. Annenkov and E. E. Safronova, "Presence of active phenylalanine hydroxylase in human leukocytes, " Voprosy Meditsinskoj Khimii, vol. 27, no. 2, pp. 266-271, 1981.
114. G. A. Annenkov, E. E. Safronova, L. M. Gubernieva, and N. M. Volkova, "Detection of phenylalanine hydroxylase activity in human leukocytes and fibroblasts, " Voprosy Meditsinskoj Khimii, vol. 26, no. 6, pp. 723-726, 1980.
115. B. A. Faraj, Z. L. Olkowski, and R. T. Jackson, "Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity, " Pharmacology, vol. 48, no. 5, pp. 320-327, 1994.
116. F. Marino, M. Cosentino, R. Bombelli, M. Ferrari, S. Lecchini, and G. Frigo, "Endogenous catecholamine synthesis, metabolism, storage, and uptake in human peripheral blood mononuclear cells, " Experimental Hematology, vol. 27, no. 3, pp. 489-495, 1999.
117. J. D. Erickson, M. K.-H. Schäfer, T. I. Bonner, L. E. Eiden, and E. Weihe, "Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 10, pp. 5166-5171, 1996.
118. M. Essand, S. Vikman, J. Grawé et al., "Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1, " Journal ofMolecular Endocrinology, vol. 35, no. 3, pp. 489-501, 2005.
119. A. Marchese, T. V. Beischlag, T. Nguyen et al., "Two gene duplication events in the human and primate dopamine D5 receptor gene family, " Gene, vol. 154, no. 2, pp. 153-158, 1995.
120. T. Nguyen, R. Sunahara, A. Marchese, H. H. M. Van Tol, P. Seeman, and B. F. O'Dowd, "Transcription of a human dopamine D5 pseudogene, " Biochemical and Biophysical Research Communications, vol. 181, no. 1, pp. 16-21, 1991.
121. D. J. E. Housley, M. Nikolas, P. J. Venta et al., "SNPdiscovery and haplotype analysis in the segmentally duplicated DRD5 coding region, " Annals of Human Genetics, vol. 73, part 3, pp. 274-282, 2009.
122. E. Josefsson, J. Bergquist, R. Ekman, and A. Tarkowski, "Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis, " Immunology, vol. 88, no. 1, pp. 140-146, 1996.
123. K. Nakano, T. Higashi, R. Takagi, K. Hashimoto, Y. Tanaka, and S. Matsushita, "Dopamine released by dendritic cells polarizes Th2differentiation, " International Immunology, vol. 21, no. 6, pp. 645-654, 2009.
124. K. Nakano, T. Higashi, K. Hashimoto, R. Takagi, Y. Tanaka, and S. Matsushita, "Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis, " Biochemical and Biophysical ResearchCommunications, vol. 373, no. 2, pp. 286-291, 2008.
125. J. Bergquist, E. Josefsson, A. Tarkovski, R. Ekman, and A. Ewing, "Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis, " Electrophoresis, vol. 18, no. 10, pp. 1760-1766, 1997.
126. A. Kavelaars, P. M. Cobelens, M. A. T. Teunis, and C. J. Heijnen, "Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene, " Journal of Neuroimmunology, vol. 161, no. 1-2, pp. 162-168, 2005.
127. H. González, F. Contreras, C. Prado et al., "Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration ofdopaminergic neurons duringparkinson's disease, " Journal of Immunology, vol. 190, no. 10, pp. 5048-5056, 2013.
128. M. G. Garca, J. G. Puig, and R. J. Torres, "Adenosine, dopamine and serotonin receptors imbalance in lymphocytes of Lesch-Nyhan patients, " Journal of Inherited Metabolic Disease, vol. 35, no. 6, pp. 1129-1135, 2012.
129. M. Giorelli, P. Livrea, and M. Trojano, "Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-, " Journal of Interferon and Cytokine Research, vol. 25, no. 7, pp. 395-406, 2005.
130. M. Zaffaroni, A. Rizzo, S. M. Baldini, A. Ghezzi, and G. Comi, "Induction and add-on therapy with mitoxantrone and Interferon beta in multiple sclerosis, " Neurological Sciences, vol. 29, supplement 2, pp. S230-S232, 2008.
131. G. E. A. Brito-Melo, R. Nicolato, A. C. P. de Oliveira et al., "Increase in dopaminergic, but not serotoninergic, receptors in T-cells as a marker for schizophrenia severity, " Journal of Psychiatric Research, vol. 46, no. 6, pp. 738-742, 2012.
132. J.-H. Lu, Y.-Q. Liu, Q.-W. Deng, Y.-P. Peng, and Y.-H. Qiu, "Dopamine D2 receptor is involved in alleviation of type II collagen-induced arthritis in mice, " BioMed Research International, vol. 2015, Article ID 496759, 9 pages, 2015.
133. L. Wei, C. Zhang, H. Y. Chen et al., "Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients, " Immunobiology, vol. 220, no. 3, pp. 323-330, 2015.
134. M. Jafari, G. Ahangari, M. Saberi, S. Samangoui, R. Torabi, and M. Zouali, "Distorted expression of dopamine receptor genes in systemic lupus erythematosus, " Immunobiology, vol. 218, no. 7, pp. 979-983, 2013.
135. A. E. Taraskina, M. N. Grunina, A. M. R. Zabotina et al., "The key proteins of dopaminergic neurotransmission of human peripheral blood lymphocytes: changed mRNA level in alcohol dependence syndrome, " Bulletin of Experimental Biology and Medicine, vol. 160, no. 2, pp. 271-274, 2015.
136. T. Biermann, D. Bönsch, U. Reulbach, J. Kornhuber, and S. Bleich, "Dopamine and N-methyl-D-aspartate receptor expression in peripheral blood of patients undergoing alcohol withdrawal, " Journal of Neural Transmission, vol. 114, no. 8, pp. 1081-1084, 2007.
137. N. Vousooghi, S. Z. Zarei, M.-S. Sadat-Shirazi, F. Eghbali, and M. R. Zarrindast, "mRNA expression of dopamine receptors in peripheral blood lymphocytes of computer game addicts, " Journal of Neural Transmission, vol. 122, no. 10, pp. 1391-1398, 2015.
138. V. Dias, E. Junn, and M. M. Mouradian, "The role of oxidative stress in Parkinson's disease, " Journal of Parkinson's Disease, vol. 3, no. 4, pp. 461-491, 2013.
139. Z. Qi, G. W. Miller, and E. O. Voit, "Computational systems analysis of dopamine metabolism, " PLoS ONE, vol. 3, no. 6, Article ID e2444, 2008.
140. T. Hiroi, S. Imaoka, and Y. Funae, "Dopamine formation from tyramine by CYP2D6, " Biochemical and Biophysical Research Communications, vol. 249, no. 3, pp. 838-843, 1998.
141. E. Bromek, A. Haduch, K. Goembiowska, and W. A. Daniel, "Cytochrome P450 mediates dopamine formation in the brain in vivo, " Journal of Neurochemistry, vol. 118, no. 5, pp. 806-815, 2011.
142. N. R. Musso, S. Brenci, F. Indiveri, and G. Lotti, "L-tyrosine and nicotine induce synthesis of L-Dopa and norepinephrine in human lymphocytes, " Journal of Neuroimmunology, vol. 74, no. 1-2, pp. 117-120, 1997.
143. N. R. Musso, S. Brenci, M. Setti, F. Indiveri, and G. Lotti, "Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes, " The Journal of Clinical Endocrinology&Metabolism, vol. 81, no. 10, pp. 3553-3557, 1996.
144. P. Uutela, L. Karhu, P. Piepponen, M. Käenmäki, R. A. Ketola, and R. Kostiainen, "Discovery of dopamine glucuronide in rat and mouse brain microdialysis samples using liquid chromatography tandem mass spectrometry, " Analytical Chemistry, vol. 81, no. 1, pp. 427-434, 2009.
145. G. Eisenhofer, M. W. Coughtrie, and D. S. Goldstein, "Dopamine sulphate: An enigma resolved, " Clinical and Experimental Pharmacology & Physiology. Supplement, vol. 26, pp. S41-S53, 1999.
146. N. T. Buu, J. Duhaime, C. Savard, L. Truong, and O. Kuchel, "Presence of conjugated catecholamines in rat brain: A new method of analysis of catecholamine sulfates, " Journal of Neurochemistry, vol. 36, no. 2, pp. 769-772, 1981.
147. D. Sulzer and L. Zecca, "Intraneuronal dopamine-quinone synthesis: A review, " Neurotoxicity Research, vol. 1, no. 3, pp. 181-195, 1999.
148. P. Muñoz, S. Huenchuguala, I. Paris, and J. Segura-Aguilar, "Dopamine oxidation and autophagy, " Parkinson's Disease, vol. 2012, Article ID920953, 13 pages, 2012.
149. A. Palumbo, M. d'Ischia, G. Misuraca, L. De Martino, and G. Prota, "Iron-and peroxide-dependent conjugation of dopamine with cysteine: oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine, " Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 1245, no. 2, pp. 255-261, 1995.
150. D. S. Goldstein, C. Holmes, Y. Sharabi, S. Brentzel, and G. Eisenhofer, "Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension, " Neurology, vol. 60, no. 8, pp. 1327-1332, 2003.
151. L. A. Snyder, J. L. Roberts, and S. C. Sealfon, "Alternative transcripts of the rat and human dopamine D3 receptor, " Biochemical and Biophysical Research Communications, vol. 180, no. 2, pp. 1031-1035, 1991.
152. K. Liu, C. Bergson, R. Levenson, and C. Schmauss, "On the origin of mRNA encoding the truncated dopamine D3-type receptor D3nf and detection of D3nf-like immunoreactivity in human brain, " The Journal of Biological Chemistry, vol. 269, no. 46, pp. 29220-29226, 1994.
153. M. Scarselli, F. Novi, G. U. Corsini, and R. Maggio, "Functional rescue of the inactive splice variant of the dopamineD3 receptor D3nf, " Brain Research, vol. 987, no. 2, pp. 244-247, 2003.
154. N. M. Richtand, Y. Liu, R. Ahlbrand, J. R. Sullivan, A. H. Newman, and R. K. McNamara, "Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression, " Synapse, vol. 64, no. 8, pp. 634-643, 2010.
155. L. M. Pritchard, A. D. Logue, B. C. Taylor et al., "Relative expression of D3 dopamine receptor and alternative splice variant D3nf mRNA in high and low responders to novelty, " Brain Research Bulletin, vol. 70, no. 4-6, pp. 296-303, 2006.
156. D. K. Grandy, Y. Zhang, C. Bouvier et al., "Multiple human D5 dopamine receptor genes: A functional receptor and two pseudogenes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 20, pp. 9175-9179, 1991.
157. J. M. Vile andP. G. Strange, "D2-likedopamine receptors are not detectable on human peripheral blood lymphocytes, " Biological Psychiatry, vol. 40, no. 9, pp. 881-885, 1996.
158. L. Santambrogio, M. Lipartiti, A. Bruni, and R. Dal Toso, "Dopamine receptors on human T-and B-lymphocytes, " Journal of Neuroimmunology, vol. 45, no. 1-2, pp. 113-119, 1993.
159. A. Ricci, E. Bronzetti, L. Felici, S. K. Tayebati, and F. Amenta, "Dopamine D4 receptor in human peripheral blood lymphocytes: A radioligand binding assay study, " Neuroscience Letters, vol. 229, no. 2, pp. 130-134, 1997.
160. A. J. Harmar, R. A. Hills, E. M. Rosser et al., "IUPHAR-DB: The IUPHAR database of G protein-coupled receptors and ion channels, " Nucleic Acids Research, vol. 37, no. 1, pp. D680-D685, 2009.
161. S. P. H. Alexander, A. P. Davenport, E. Kelly et al., "The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors, " British Journal of Pharmacology, vol. 172, no. 24, pp. 5744-5869, 2015.
162. S. Brogi, A. Tafi, L. Désaubry, and C. G. Nebigil, "Discovery of GPCR ligands for probing signal transduction pathways, " Frontiers in Pharmacology, vol. 5, article 255, 2014.
163. W. M. Oldham and H. E. Hamm, "Heterotrimeric G protein activation by G-protein-coupled receptors, " Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 60-71, 2008.
164. G. B. Downes and N. Gautam, "The G protein subunit gene families, " Genomics, vol. 62, no. 3, pp. 544-552, 1999.
165. S. Hernádez-López, T. Tkatch, E. Perez-Garci et al., "D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC1-IP3-calcineurin-signaling cascade, " The Journal of Neuroscience, vol. 20, no. 24, pp. 8987-8995, 2000.
166. S. Ahn, S. K. Shenoy, H. Wei, and R. J. Lefkowitz, "Differential kinetic and spatial patterns of-arrestin and G proteinmediated ERK activation by the angiotensin II receptor, " The Journal of Biological Chemistry, vol. 279, no. 34, pp. 35518-35525, 2004.
167. S. Amar, G. Shaltiel, L. Mann et al., "Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia, " International Journal of Neuropsychopharmacology, vol. 11, no. 2, pp. 197-205, 2008.
168. K. A. Harrington, S. J. Augood, A. E. Kingsbury, O. J. F. Foster, and P. C. Emson, "Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease, " Molecular Brain Research, vol. 36, no. 1, pp. 157-162, 1996.
169. T. S. Guillot, J. R. Richardson, M. Z. Wang et al., "PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity, " Neuropeptides, vol. 42, no. 4, pp. 423-434, 2008.
170. E. Floor, S. F. Schaeffer, B. E. Feist, and S. E. Leeman, "Synaptic vesicles from mammalian brain: large-scale purification and physical and immunochemical characterization, " Journal of Neurochemistry, vol. 50, no. 5, pp. 1588-1596, 1988.
171. W. Lu and M. E. Wolf, "Expression of dopamine transporter and vesicularmonoamine transporter 2mRNAs in rat midbrain after repeated amphetamine administration, " Molecular Brain Research, vol. 49, no. 1-2, pp. 137-148, 1997.
172. G. W. Miller, J. D. Erickson, J. T. Perez et al., "Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease, " Experimental Neurology, vol. 156, no. 1, pp. 138-148, 1999.
173. K. Wimalasena, "Vesicular monoamine transporters: structurefunction, pharmacology, and medicinal chemistry, " Medicinal Research Reviews, vol. 31, no. 4, pp. 483-519, 2011.
174. M. B. Larsen, M. S. Sonders, O. V. Mortensen, G. A. Larson, N. R. Zahniser, and S. G. Amara, "Dopamine transport by the serotonin transporter: A mechanistically distinct mode of substrate translocation, " The Journal of Neuroscience, vol. 31, no. 17, pp. 6605-6615, 2011.
175. S. M. Parsons, "Transport mechanisms in acetylcholine and monoamine storage, " The FASEB Journal, vol. 14, no. 15, pp. 2423-2434, 2000.
176. B. Gasnier, "The loading of neurotransmitters into synaptic vesicles, " Biochimie, vol. 82, no. 4, pp. 327-337, 2000.
177. M. Forgac, "Structure and properties of the vacuolar (H+)-ATPases, " The Journal of Biological Chemistry, vol. 274, no. 19, pp. 12951-12954, 1999.
178. N. Nelson andW. R. Harvey, "Vacuolar and plasma membrane proton-adenosinetriphosphatases, " Physiological Reviews, vol. 79, no. 2, pp. 361-385, 1999.
179. D. Marazziti, S. Baroni, M. Catena Dell'Osso et al., "Presence and characterization of the dopamine transporter in human resting lymphocytes, " Neurochemical Research, vol. 33, no. 6, pp. 1011-1016, 2008.
180. J. Mill, P. Asherson, C. Browes, U. D'Souza, and I. Craig, "Expression of the dopamine transporter gene is regulated by the 3 UTR VNTR: Evidence frombrain and lymphocytes using quantitative RT-PCR, " American Journal of Medical Genetics-Neuropsychiatric Genetics, vol. 114, no. 8, pp. 975-979, 2002.
181. F. W. Lohoff, J. P. Dahl, T. N. Ferraro et al., "Variations in the vesicularmonoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder, " Neuropsychopharmacology, vol. 31, no. 12, pp. 2739-2747, 2006.
182. F. W. Lohoff, R. Hodge, S. Narasimhanet al., "Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing, "Molecular Psychiatry, vol. 19, no. 1, pp. 129-139, 2014.
183. E. Y. T. Chien, W. Liu, Q. Zhao et al., "Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist, " Science, vol. 330, no. 6007, pp. 1091-1095, 2010.
184. V. Olivares-Illana, R. Arreola, A. Gómez-Poyou, and R. Pérez-Montfort, "Proteins and drug discovery (development), " in Advances in Protien Physical Chemistry, E. Garca-Hernández and D. A. Fernández-Velasco, Eds., p. 501, Transworld Research Network, Thiruvananthapuram, India, 1st edition, 2008.
185. M. J. Wasko, K. A. Pellegrene, J. D. Madura, and C. K. Surratt, "A role for fragment-based drug design in developing novel lead compounds for central nervous system targets, " Frontiers in Neurology, vol. 6, article 197, 2015.
186. R. Pacheco, C. E. Prado, M. J. Barrientos, and S. Bernales, "Role of dopamine in the physiology of T-cells and dendritic cells, " Journal of Neuroimmunology, vol. 216, no. 1-2, pp. 8-19, 2009.
187. M. Cosentino, F. Marino, and G. J. M. Maestroni, "Sympathoadrenergic modulation of hematopoiesis: A review of available evidence and of therapeutic perspectives, " Frontiers in Cellular Neuroscience, vol. 9, article 302, 2015.
188. A. Spiegel, A. Kalinkovich, S. Shivtiel, O. Kollet, and T. Lapidot, "Stem cell regulation via dynamic interactions of the nervous and immune systems with the microenvironment, " Cell Stem Cell, vol. 3, no. 5, pp. 484-492, 2008.
189. G. J. M. Maestroni, A. Conti, and E. Pedrinis, "Effect of adrenergic agents on hematopoiesis after syngeneic bone marrow transplantation in mice, " Blood, vol. 80, no. 5, pp. 1178-1182, 1992.
190. A. Spiegel, S. Shivtiel, A. Kalinkovich et al., "Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling, " Nature Immunology, vol. 8, no. 10, pp. 1123-1131, 2007.
191. M. Cosentino, M. Ferrari, N. Kustrimovic, E. Rasini, and F. Marino, "Influence of dopamine receptor gene polymorphisms on circulating T lymphocytes: A pilot study in healthy subjects, " Human Immunology, vol. 76, no. 10, pp. 747-752, 2015.
192. C. Sarkar, D. Chakroborty, P. S. Dasgupta, and S. Basu, "Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia, " International Journal of Cancer, vol. 137, no. 3, pp. 744-749, 2015.
193. L. Pavon, M. Jiménez-Martnez, and M. Garces-Alvarez, Inmunologa Molecular, Celular y Traslacional, Kluwer Academic Publishers, Philadelphia, Pa, USA, 2016.
194. M. Cosentino, F. Marino, R. Bombelli, M. Ferrari, S. Lecchini, and G. Frigo, "Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils, " Life Sciences, vol. 64, no. 11, pp. 975-981, 1999.
195. C. Wenisch, B. Parschalk, A. Weiss et al., "High-dose catecholamine treatment decreases polymorphonuclear leukocyte phagocytic capacity and reactive oxygen production, " Clinical and Diagnostic Laboratory Immunology, vol. 3, no. 4, pp. 423-428, 1996.
196. S. Sookhai, J. H. Wang, M. McCourt, D. O'Connell, and H. P. Redmond, "Dopamine induces neutrophil apoptosis through a dopamine D-1 receptor-independent mechanism, " Surgery, vol. 126, no. 2, pp. 314-322, 1999.
197. S. Sookhai, J. H. Wang, D. Winter, C. Power, W. Kirwan, andH. P. Redmond, "Dopamine attenuates the chemoattractant effect of interleukin-8: A novel role in the systemic inflammatory response syndrome, " Shock, vol. 14, no. 3, pp. 295-299, 2000.
198. B. Trabold, M. Gruber, and D. Fröhlich, "Functional and phenotypic changes in polymorphonuclear neutrophils induced by catecholamines, " Scandinavian Cardiovascular Journal, vol. 41, no. 1, pp. 59-64, 2007.
199. M. Cosentino, R. Bombelli, M. Ferrari et al., "HPLC-ED measurement of endogenous catecholamines in human immune cells and hematopoietic cell lines, " Life Sciences, vol. 68, no. 3, pp. 283-295, 2000.
200. R. A. Ali, M. A. Qureshi, andF. M. McCorkle, "Profileof chicken macrophage functions after exposure to catecholamines in vitro, " Immunopharmacology and Immunotoxicology, vol. 16, no. 4, pp. 611-625, 1994.
201. G. Haskó, C. Szabó, K. Merkel et al., "Modulation of lipopolysaccharide-induced tumor necrosis factor-and nitric oxide production by dopamine receptor agonists and antagonists in mice, " Immunology Letters, vol. 49, no. 3, pp. 143-147, 1996.
202. F. Gomez, P. Ruiz, F. Briceño, C. Rivera, and R. Lopez, "Macrophage Fc receptors expression is altered by treatment with dopaminergic drugs, " Clinical Immunology, vol. 90, no. 3, pp. 375-387, 1999.
203. J. Bergquist, B. Ohlsson, and A. Tarkowski, "Nuclear factorkappa B is involved in the catecholaminergic suppression of immunocompetent cells, " Annals of the New York Academy of Sciences, vol. 917, pp. 281-289, 2000.
204. G. Haskó, C. Szabó, Z. H. Németh, and E. A. Deitch, "Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a-adrenoceptor-mediated mechanism, " Journal of Neuroimmunology, vol. 122, no. 1-2, pp. 34-39, 2002.
205. O. Rohr, B. E. Sawaya, D. Lecestre, D. Aunis, and E. Schaeffer, "Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-B in cells of the immune system, " Nucleic Acids Research, vol. 27, no. 16, pp. 3291-3299, 1999.
206. E. A. Berger, P. M. Murphy, and J. M. Farber, "Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease, " Annual Review of Immunology, vol. 17, pp. 657-700, 1999.
207. J. Wang, K. Crawford, M. Yuan, H. Wang, P. R. Gorry, and D. Gabuzda, "Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines, " Journal of Infectious Diseases, vol. 185, no. 7, pp. 885-897, 2002.
208. S. Sozzani, S. Ghezzi, G. Iannolo et al., "Interleukin 10 increases CCR5 expression and HIV infection in humanmonocytes, " The Journal of Experimental Medicine, vol. 187, no. 3, pp. 439-444, 1998.
209. P. J. Gaskill, H. H. Yano, G. V. Kalpana, J. A. Javitch, and J. W. Berman, "Dopamine receptor activation increases HIV entry into primary human macrophages, " PLoS ONE, vol. 9, no. 9, Article ID e108232, 2014.
210. J. Bergquist and J. Silberring, "Identification of catecholamines in the immune system by electrospray ionization mass spectrometry, " Rapid Communications inMass Spectrometry, vol. 12, no. 11, pp. 683-688, 1998.
211. Y. H. Qiu, Y. P. Peng, J. M. Jiang, and J. J. Wang, "Expression of tyrosine hydroxylase in lymphocytes and effect of endogenous catecholamines on lymphocyte function, " Neuroimmunomodulation, vol. 11, no. 2, pp. 75-83, 2004.
212. A. Ricci, L. Chiandussi, M. Schena, D. Schiavone, F. Veglio, and F. Amenta, "Dopamine D5 receptor expression is unchanged in peripheral blood lymphocytes in essential hypertension, " Clinical and Experimental Hypertension, vol. 17, no. 8, pp. 1157-1172, 1995.
213. M. Levite, Y. Chowers, Y. Ganor, M. Besser, R. Hershkovits, and L. Cahalon, "Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates 1 integrin function, " European Journal of Immunology, vol. 31, no. 12, pp. 3504-3512, 2001.
214. B. Saha, A. C. Mondal, S. Basu, and P. S. Dasgupta, "Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: An in vitro analysis, " International Immunopharmacology, vol. 1, no. 7, pp. 1363-1374, 2001.
215. B. Saha, A. C. Mondal, J. Majumder, S. Basu, and P. S. Dasgupta, "Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of humanCD4+ andCD8+ Tcells invitro: A receptor-mediated mechanism, " NeuroImmunoModulation, vol. 9, no. 1, pp. 23-33, 2001.
216. C.-W. Tsao, Y.-S. Lin, and J.-T. Cheng, "Effect of dopamine on immune cell proliferation in mice, " Life Sciences, vol. 61, no. 24, pp. PL361-PL371, 1997.
217. L. Carr, A. Tucker, and R. Fernandez-Botran, "In vivo administration of l-dopa or dopamine decreases the number of splenic IFN-producing cells, " Journal of Neuroimmunology, vol. 137, no. 1-2, pp. 87-93, 2003.
218. K. Nakagome, M. Imamura, H. Okada et al., "Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation, " Journal of Immunology, vol. 186, no. 10, pp. 5975-5982, 2011.
219. J. M. Cook-Mills, R. L. Cohen, R. L. Perlman, and D. A. Chambers, "Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action, " Immunology, vol. 85, no. 4, pp. 544-549, 1995.
220. T. Mori, K. Kabashima, S. Fukamachi et al., "D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells, " Journal of Dermatological Science, vol. 71, no. 1, pp. 37-44, 2013.
221. P. S. Dasgupta and T. Lahiri, "Antitumor effect of i. p. dopamine in mice bearing Ehrlich ascites carcinoma, " Journal of Cancer Research and Clinical Oncology, vol. 113, no. 4, pp. 363-368, 1987.
222. S. Basu, P. S. Dasgupta, M. R. Ray, and T. Lahiri, "Stimulation of NK activity in Ehrlich ascites carcinoma-bearing mice following dopamine treatment, " Biogenic Amines, vol. 8, article 7, 1992.
223. M. A. T. Teunis, C. J. Heijnen, A. R. Cools, and A. Kavelaars, "Reduced splenic natural killer cell activity in rats with a hyperreactive dopaminergic system, " Psychoneuroendocrinology, vol. 29, no. 8, pp. 1058-1064, 2004.
224. K. S. Madden, V. M. Sanders, and D. L. Felten, "Catecholamine influences and sympathetic neural modulation of immune responsiveness, " Annual Review of Pharmacology and Toxicology, vol. 35, pp. 417-448, 1995.
225. Y. Huang, Z. Liu, X. Q. Wang, and Y. H. Qiu, "A dysfunction of CD4+ T lymphocytes in peripheral immune system of Parkinson's disease model mice, " Zhongguo Ying Yong Sheng Li Xue Za Zhi, vol. 30, no. 6, pp. 567-576, 2014.
226. S. Basu, P. S. Dasgupta, and J. R. Chowdhury, "Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treatment, " Journal of Neuroimmunology, vol. 60, no. 1-2, pp. 1-8, 1995.
227. B. Deleplanque, S. Vitiello, M. Le Moal, and P. J. Neveu, "Modulation of immune reactivity by unilateral striatal and mesolimbic dopaminergic lesions, " Neuroscience Letters, vol. 166, no. 2, pp. 216-220, 1994.
228. P. Barbanti, G. Fabbrini, A. Ricci et al., "Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease, "Mechanisms ofAgeing andDevelopment, vol. 120, no. 1-3, pp. 65-75, 2000.
229. M. Cosentino, C. Colombo, M. Mauri et al., "Expression of Apoptosis-related Proteins and of mRNA for dopaminergic receptors in peripheral blood mononuclear cells from patients with Alzheimer disease, " Alzheimer Disease and Associated Disorders, vol. 23, no. 1, pp. 88-90, 2009.
230. F. Giubilei, C. Calderaro, G. Antonini et al., "Increased lymphocyte dopamine-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit" Dementia and Geriatric Cognitive Disorders, vol. 18, no. 3-4, pp. 338-341, 2004.
231. Y. T. Kwak, M.-S. Koo, C.-H. Choi, and I. N. Sunwoo, "Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients, " BMC Medical Genetics, vol. 2, article 3, 2001.
232. T. Ilani, D. Ben-Shachar, R. D. Strous et al., "Aperipheralmarker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 2, pp. 625-628, 2001.
233. E. M. Boneberg, E. von Seydlitz, K. Pröpster, H. Watzl, B. Rockstroh, and H. Illges, "D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+-T cells, " Journal of Neuroimmunology, vol. 173, no. 1-2, pp. 180-187, 2006.
234. M. Vogel, S. Pfeifer, R. T. Schaub et al., "Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients, " Neuropsychobiology, vol. 50, no. 4, pp. 305-310, 2004.
235. Á. Zvara, G. Szekeres, Z. Janka et al., "Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic peripheral blood lymphocytes as potential diagnostic markers, " DiseaseMarkers, vol. 21, no. 2, pp. 61-69, 2005.
236. M. Urhan-Kucuk, M. E. Erdal, M. E. Ozen, S. Kul, and H. Herken, "Is the dopamine D3 receptor mRNA on blood lymphocytes help to for identification and subtyping of schizophrenia" Molecular Biology Reports, vol. 38, no. 4, pp. 2569-2572, 2011.
237. Y. Cui, V. Prabhu, T. B. Nguyen, B. K. Yadav, and Y.-C. Chung, "The mRNA expression status of dopamine receptor D2, dopamine receptor D3 and DARPP-32 in T lymphocytes of patients with early psychosis, " International Journal ofMolecular Sciences, vol. 16, no. 11, pp. 26677-26686, 2015.
238. F. Marino and M. Cosentino, "Multiple sclerosis: repurposing dopaminergic drugs for MS-the evidence mounts, " Nature Reviews Neurology, vol. 12, no. 4, pp. 191-192, 2016.
239. J. S. Tzartos, M. A. Friese, M. J. Craner et al., "Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, " The American Journal of Pathology, vol. 172, no. 1, pp. 146-155, 2008.
240. M. Cosentino, M. Zaffaroni, M. Ferrari et al., "Interferon-and interferon-affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis, " Journal of Neuroimmunology, vol. 162, no. 1-2, pp. 112-121, 2005.
241. M. Cosentino, M. Zaffaroni, and F. Marino, "Levels of mRNA for dopaminergic receptor D5 in circulating lymphocytes may be associated with subsequent response to interferon-in patients with multiple sclerosis, " Journal of Neuroimmunology, vol. 277, no. 1-2, pp. 193-196, 2014.
242. E. Bakowiec-Iskra, I. Kurkowska-Jastrzebska, I. Joniec et al., "MPTP-induced central dopamine depletion exacerbates experimental autoimmune encephalomyelitis (EAE) in C57BL mice, " Inflammation Research, vol. 56, no. 8, pp. 311-317, 2007.
243. T. Lowin and R. H. Straub, "Synovial fibroblasts integrate inflammatory and neuroendocrine stimuli to drive rheumatoid arthritis, " Expert Review of Clinical Immunology, vol. 11, no. 10, pp. 1069-1071, 2015.
244. S. Capellino, M. Cosentino, A. Luini et al., "Increased expression of dopamine receptors in synovial fibroblasts frompatients with rheumatoid arthritis: inhibitory effects of dopamine on interleukin-8 and interleukin-6, " Arthritis and Rheumatology, vol. 66, no. 10, pp. 2685-2693, 2014.
245. M. Levite, "Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases, " Acta Physiologica, vol. 216, no. 1, pp. 42-89, 2016.
246. K. Nakano, K. Yamaoka, K. Hanami et al., "Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/ SCID mouse chimera model, " Journal of Immunology, vol. 186, no. 6, pp. 3745-3752, 2011.
247. M. Mobini, Z. Kashi, A. R. MohammadPour, andE. Adibi, "The effect of cabergoline on clinical and laboratory findings in active rheumatoid arthritis, " Iranian Red CrescentMedical Journal, vol. 13, no. 10, pp. 749-750, 2011.
248. R. Pacheco, F. Contreras, and M. Zouali, "The dopaminergic system in autoimmune diseases, " Frontiers in Immunology, vol. 5, article 117, 2014.
249. S. J. Chadban and R. C. Atkins, "Glomerulonephritis, " The Lancet, vol. 365, no. 9473, pp. 1797-1806, 2005.
250. T. Hussain and M. F. Lokhandwala, "Renal dopamine receptor function in hypertension, " Hypertension, vol. 32, no. 2, pp. 187-197, 1998.
251. S. Hoeger, U. Gottmann, Z. Liu et al., "Dopamine treatment in brain-dead rats mediates anti-inflammatory effects: The role of hemodynamic stabilization and D-receptor stimulation, " Transplant International, vol. 20, no. 9, pp. 790-799, 2007.
252. S. Hoeger, A. Reisenbuechler, U. Gottmann et al., "Donor dopamine treatment in brain dead rats is associated with an improvement in renal function early after transplantation and a reduction in renal inflammation, " Transplant International, vol. 21, no. 11, pp. 1072-1080, 2008.
253. S. Kapper, G. Beck, S. Riedel et al., "Modulation of chemokine production and expression of adhesion molecules in renal tubular epithelial and endothelial cells by catecholamines, " Transplantation, vol. 74, no. 2, pp. 253-260, 2002.
254. D. Chakroborty, C. Sarkar, B. Basu, P. S. Dasgupta, and S. Basu, "Catecholamines regulate tumor angiogenesis, " Cancer Research, vol. 69, no. 9, pp. 3727-3730, 2009.
255. H. F. Dvorak, "Angiogenesis: update 2005, " Journal ofThrombosis and Haemostasis, vol. 3, no. 8, pp. 1835-1842, 2005.
256. D. D. Feng, W. Cai, and X. Chen, "The associations between Parkinson's disease and cancer: The plot thickens, " Translational Neurodegeneration, vol. 4, article 20, 2015.
257. C. Sarkar, B. Basu, D. Chakroborty, P. S. Dasgupta, and S. Basu, "The immunoregulatory role of dopamine: An update, " Brain, Behavior, and Immunity, vol. 24, no. 4, pp. 525-528, 2010.
258. R. Hodgson, H. J. Wildgust, and C. J. Bushe, "Cancer and schizophrenia: is there a paradox" Journal of Psychopharmacology, vol. 24, no. 4, supplement, pp. 51-60, 2010.
259. M. Asada, S. Ebihara, Y. Numachi et al., "Reducedtumor growth in a mouse model of schizophrenia, lacking the dopamine transporter, " International Journal of Cancer, vol. 123, no. 3, pp. 511-518, 2008.
260. J. A. Driver, G. Logroscino, J. E. Buring, J. M. Gaziano, and T. Kurth, "A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease, " Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 6, pp. 1260-1265, 2007.
261. E. Sachlos, R. M. Risueño, S. Laronde et al., "Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells, " Cell, vol. 149, no. 6, pp. 1284-1297, 2012.
262. C. Sarkar, D. Chakroborty, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu, "Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 287, no. 4, pp. H1554-H1560, 2004.
263. S. Basu, J. A. Nagy, S. Pal et al., "The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/ vascular endothelial growth factor, " Nature Medicine, vol. 7, no. 5, pp. 569-574, 2001.
264. D. Chakroborty, C. Sarkar, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu, "Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis, " Clinical Cancer Research, vol. 10, no. 13, pp. 4349-4356, 2004.
265. S. Ganguly, B. Basu, S. Shome et al., "Dopamine, by acting through Its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via upregulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation, " American Journal of Pathology, vol. 177, no. 6, pp. 2701-2707, 2010.
266. S. Basu, C. Sarkar, D. Chakroborty et al., "Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis, " Cancer Research, vol. 64, no. 16, pp. 5551-5555, 2004.
267. D. Chakroborty, C. Sarkar, H. Yu et al., "Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 51, pp. 20730-20735, 2011.
268. F. Lopez Vicchi, G. M. Luque, B. Brie, J. P. Nogueira, I. Garcia Tornadu, and D. Becu-Villalobos, "Dopaminergic drugs in type 2 diabetes and glucose homeostasis, " Pharmacological Research, vol. 109, pp. 74-80, 2016.
269. American Diabetes Association, "Diagnosis and classification of diabetes mellitus, " Diabetes Care, vol. 29, supplement 1, pp. S43-S48, 2006.
270. B. J. Davis and P. H. Smith, "Effects of substantia nigra lesions on the volumes of A, B, and D cells and the content of insulin and glucagon in the rat pancreas, " Diabetologia, vol. 28, no. 10, pp. 756-762, 1985.
271. B. Rubi, S. Ljubicic, S. Pournourmohammadi et al., "Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion, "TheJournal of Biological Chemistry, vol. 280, no. 44, pp. 36824-36832, 2005.
272. Y. Zhang, R. Zheng, X. Meng, L. Wang, L. Liu, and Y. Gao, "Pancreatic endocrine effects of dopamine receptors in human islet cells, " Pancreas, vol. 44, no. 6, pp. 925-929, 2015.
273. Y. Chen, F. Hong, H. Chen et al., "Distinctive expression and cellular distribution of dopamine receptors in the pancreatic islets of rats, " Cell and Tissue Research, vol. 357, no. 3, pp. 597-606, 2014.
274. E. Shankar, K. T. Santhosh, and C. S. Paulose, "Dopaminergic regulation of glucose-induced insulin secretion through dopamineD2 receptors in the pancreatic islets in vitro, " IUBMB Life, vol. 58, no. 3, pp. 157-163, 2006.
275. K. Melkersson, A. Khan, A. Hilding, and A. L. Hulting, "Different effects of antipsychotic drugs on insulin release in vitro, " European Neuropsychopharmacology, vol. 11, no. 5, pp. 327-332, 2001.
276. W. Wu, J. Shang, Y. Feng et al., "Identification of glucosedependent insulin secretion targets in pancreatic cells by combining defined-mechanism compound library screening and siRNA gene silencing, " Journal of Biomolecular Screening, vol. 13, no. 2, pp. 128-134, 2008.
277. I. Garca-Tornadú, A. M. Ornstein, A. Chamson-Reig et al., "Disruption of the dopamine D2 receptor impairs insulin secretion and causes glucose intolerance, " Endocrinology, vol. 151, no. 4, pp. 1441-1450, 2010.
278. A. Ustione, D. W. Piston, and P. E. Harris, "Minireview: dopaminergic regulation of insulin secretion from the pancreatic islet, "Molecular Endocrinology, vol. 27, no. 8, pp. 1198-1207, 2013.
279. K. Hashimoto, T. Inoue, T. Higashi et al., "Dopamine D1-like receptor antagonist, SCH23390, exhibits a preventive effect on diabetes mellitus that occurs naturally in NOD mice, " Biochemical and Biophysical Research Communications, vol. 383, no. 4, pp. 460-463, 2009.
280. A. Goodarzi, N. Vousooghi, M. Sedaghati, A. Mokri, and M.-R. Zarrindast, "Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction, " European Journal of Pharmacology, vol. 615, no. 1-3, pp. 218-222, 2009.
281. N. D. Volkow, G.-J. Wang, J. S. Fowler, and D. Tomasi, "Addiction circuitry in the human brain, " Annual Review of Pharmacology and Toxicology, vol. 52, pp. 321-336, 2012.
282. C. Czermak, M. Lehofer, H. Renger et al., "Dopamine receptor D3 mRNA expression in human lymphocytes is negatively correlated with the personality trait of persistence, " Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 145-149, 2004.